Radiant Sage Appoints Robert Ford , MD, As Adjunct Chief Medical Advisor

BELMONT, MA--(Marketwired - January 12, 2016) - Radiant Sage LLC, a provider of on-demand clinical trial imaging infrastructure solutions and services, today announced that Robert Ford, MD, has been named as its Chief Medical Advisor. In this adjunct role, Dr. Ford will share his medical expertise to help Radiant Sage deliver high quality medical services to its clients from trial design and document development to trial oversight and regulatory filings. In addition, Dr. Ford will play a key role in providing practical insight for both technology development and medical services.

"We are thrilled to have Dr. Ford join our team," said Venkatesan Thangaraj, Radiant Sage's CEO. "He is a recognized expert within the corelab industry and will be a valuable resource for our clients, services staff and technical team while they develop clinical trial image management solutions and deliver high quality clinical trial services. We look forward to leveraging his expansive knowledge of clinical trials."

In 1998, Dr. Ford founded RadPharm, an imaging corelab dedicated to the independent review of diagnostic imaging studies for the pharmaceutical and regulatory agencies, primarily the United States Food and Drug Administration (FDA). Between 1998 and 2008, Dr. Ford was the president and Chief Medical Officer (CMO) at RadPharm. As CMO, he was a reviewer or supervised the independent radiologic review of images from approximately 300 clinical trials involving tens of thousands of patients, primarily in the oncology therapeutic area. In addition, during that time, he worked with the FDA and pharmaceutical companies for the approval of Herceptin, Eloxatin, Velcade, Sutent, Vectibix, Ixempra, Treanda, Doxil, Avastin, and Pegloticase.

Dr. Ford was a co-author of the Response Evaluation Criteria of Solid Tumors (RECIST 1.1), an internationally accepted response criteria that is used to standardize patient response to therapy.

About Radiant Sage
Radiant Sage provides game-changing clinical trial imaging infrastructure solutions and services for organizations involved in drug discovery and research. Specifically designed for clinical trials, the company's solutions, RadClinica™, Core-Lab-in-a-Box™ and RadVista™ Viewer are extremely flexible and offer self-contained customization tools enabling rapid trial start and increased overall efficiency of the collection, distribution, processing, and analysis of clinical trial imaging data. The use of Radiant Sage's technologies provide sponsors with the ability to retain control of their clinical trials by leveraging these cost-effective image management solutions designed with real-time transparency in reporting at every level of the entire process. These secure and validated tools also offer increased image/data integrity over current corelab processes and meet all necessary compliance requirements. Founded in 2008, Radiant Sage is headquartered in Boston, Mass. For more information on Radiant Sage, visit www.radiantsage.com. 


Contact:
Karen Higgins
A&E Communications, Inc.
610-831-5723
Email Contact

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.